Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VINC
- Price
- 0.28
- Stock movement up
- +- (%)
- Company name
- Vincerx Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 424.61K
- Ent value
- 3.32M
- Price/Sales
- 0.32
- Price/Book
- 0.05
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -98.54%
- 3 year return
- -83.48%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VINC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.32 |
| Price to Book | 0.05 |
| EV to Sales | 2.53 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.54M |
| EPS (TTM) | -11.84 |
| FCF per share (TTM) | -12.25 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.31M |
| Gross profit (TTM) | 522.00K |
| Operating income (TTM) | -28.17M |
| Net income (TTM) | -27.03M |
| EPS (TTM) | -11.84 |
| EPS (1y forward) | -13.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 39.73% |
| Operating margin (TTM) | -2143.84% |
| Profit margin (TTM) | -2057.08% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.94M |
| Net receivables | 1.06M |
| Total current assets | 11.75M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 14.95M |
| Accounts payable | 1.96M |
| Short/Current long term debt | 1.64M |
| Total current liabilities | 5.42M |
| Total liabilities | 5.84M |
| Shareholder's equity | 9.11M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.96M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -27.96M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -296.77% |
| Return on Assets | -180.84% |
| Return on Invested Capital | -260.35% |
| Cash Return on Invested Capital | -269.36% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.28 |
| Daily high | 0.28 |
| Daily low | 0.28 |
| Daily Volume | 0K |
| All-time high | 518.00 |
| 1y analyst estimate | 120.00 |
| Beta | 1.27 |
| EPS (TTM) | -11.84 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| VINC | S&P500 | |
| Current price drop from All-time high | -99.95% | -14.12% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 14 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -71.45% | -11.07% |
| Avg time to new high | 36 days | 12 days |
| Max time to new high | 1029 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
424.61K
Marketcap category
Small-cap
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Employees
42
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page